Literature DB >> 26663867

Use of nanoparticles to deliver immunomodulatory oligonucleotides.

Dennis M Klinman1, Takashi Sato2, Takeshi Shimosato3.   

Abstract

Synthetic oligonucleotides (ODNs) containing unmethylated 'CpG motifs' stimulate the innate immune system to produce cytokines, chemokines, and polyreactive antibodies. CpG ODNs have shown promise as vaccine adjuvants and for the treatment of infectious diseases and cancer. The immunostimulatory activity of CpG ODNs is inhibited by DNA-containing 'suppressive' motifs. ODNs expressing suppressive motifs (Sup ODNs) reduce ongoing immune reactions and show promise in the treatment of autoimmune and inflammatory diseases. This work reviews recent progress in the use of nanoparticles as carriers of CpG and Sup ODNs to target their delivery to the GI tract and lungs. WIREs Nanomed Nanobiotechnol 2016, 8:631-637. doi: 10.1002/wnan.1382 For further resources related to this article, please visit the WIREs website.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26663867      PMCID： PMC4903938          DOI： 10.1002/wnan.1382

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN： 1939-0041


  59 in total

1.  Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation.

Authors:  Ihsan Gursel; Mayda Gursel; Hiroshi Yamada; Ken J Ishii; Fumihiko Takeshita; Dennis M Klinman
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

2.  CpG oligodeoxynucleotides induce strong up-regulation of interleukin 33 via Toll-like receptor 9.

Authors:  Takeshi Shimosato; Megumi Fujimoto; Masanori Tohno; Takashi Sato; Mariko Tateo; Hajime Otani; Haruki Kitazawa
Journal:  Biochem Biophys Res Commun       Date:  2010-02-21       Impact factor: 3.575

Review 3.  Inhaled nanoparticles--a current review.

Authors:  Wei Yang; Jay I Peters; Robert O Williams
Journal:  Int J Pharm       Date:  2008-02-16       Impact factor: 5.875

4.  Bacterial DNA causes septic shock.

Authors:  T Sparwasser; T Miethke; G Lipford; K Borschert; H Häcker; K Heeg; H Wagner
Journal:  Nature       Date:  1997-03-27       Impact factor: 49.962

5.  Analysis of tumor vessel supply in Lewis lung carcinoma in mice by fluorescent microsphere distribution and imaging with micro- and flat-panel computed tomography.

Authors:  Rajkumar Savai; Joachim C Wolf; Susanne Greschus; Bastian G Eul; Ralph T Schermuly; Jörg Hänze; Robert Voswinckel; Alexander C Langheinrich; Friedrich Grimminger; Horst Traupe; Werner Seeger; Frank Rose
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

6.  A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

Authors:  C Manegold; N van Zandwijk; A Szczesna; P Zatloukal; J S K Au; M Blasinska-Morawiec; P Serwatowski; M Krzakowski; J Jassem; E H Tan; R J Benner; A Ingrosso; S J Meech; D Readett; N Thatcher
Journal:  Ann Oncol       Date:  2011-04-04       Impact factor: 32.976

7.  An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems.

Authors:  Peggy P Ho; Paulo Fontoura; Pedro J Ruiz; Lawrence Steinman; Hideki Garren
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

8.  A glucose carbonate apatite complex exhibits in vitro and in vivo anti-tumour effects.

Authors:  Hirofumi Yamamoto; Xin Wu; Hiroyuki Nakanishi; Yuki Yamamoto; Mamoru Uemura; Taishi Hata; Junichi Nishimura; Ichiro Takemasa; Tsunekazu Mizushima; Jun-Ichi Sasaki; Satoshi Imazato; Nariaki Matsuura; Yuichiro Doki; Masaki Mori
Journal:  Sci Rep       Date:  2015-01-13       Impact factor: 4.379

9.  Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors.

Authors:  By Gan Zhao; John P Vasilakos; Debra Tross; Dmitri Smirnov; Dennis M Klinman
Journal:  J Immunother Cancer       Date:  2014-05-13       Impact factor: 13.751

10.  Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection.

Authors:  Qing Zhu; James Talton; Guofeng Zhang; Tshaka Cunningham; Zijian Wang; Robert C Waters; James Kirk; Bärbel Eppler; Dennis M Klinman; Yongjun Sui; Susan Gagnon; Igor M Belyakov; Russell J Mumper; Jay A Berzofsky
Journal:  Nat Med       Date:  2012-07-15       Impact factor: 53.440
View more
  5 in total

1.  Immunological properties of gold nanoparticles.

Authors:  Lev A Dykman; Nikolai G Khlebtsov
Journal:  Chem Sci       Date:  2016-11-16       Impact factor: 9.825

Review 2.  Nanoparticle-allergen complexes for allergen immunotherapy.

Authors:  Gabriella Di Felice; Paolo Colombo
Journal:  Int J Nanomedicine       Date:  2017-06-19

Review 3.  Applications of Gold Nanoparticles in Nanomedicine: Recent Advances in Vaccines.

Authors:  Sónia Alexandra Correia Carabineiro
Journal:  Molecules       Date:  2017-05-22       Impact factor: 4.411

4.  Free Feeding of CpG-Oligodeoxynucleotide Particles Prophylactically Attenuates Allergic Airway Inflammation and Hyperresponsiveness in Mice.

Authors:  Takuma Okajima; Suguru Shigemori; Fu Namai; Tasuku Ogita; Takashi Sato; Takeshi Shimosato
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 7.561

Review 5.  Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines.

Authors:  Romina Mitarotonda; Exequiel Giorgi; Tatiane Eufrasio-da-Silva; Alireza Dolatshahi-Pirouz; Yogendra Kumar Mishra; Ali Khademhosseini; Martin F Desimone; Mauricio De Marzi; Gorka Orive
Journal:  Biomater Adv       Date:  2022-04-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.